Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · IEX Real-Time Price · USD
3.270
+0.170 (5.48%)
At close: May 1, 2024, 4:00 PM
3.050
-0.220 (-6.73%)
After-hours: May 1, 2024, 6:43 PM EDT
Leap Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Leap Therapeutics stock have an average target of 11.38, with a low estimate of 7.00 and a high estimate of 17.5. The average target predicts an increase of 248.01% from the current stock price of 3.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2024.
Analyst Ratings
The average analyst rating for LPTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +175.23% | Mar 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +114.07% | Mar 19, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +266.97% | Nov 20, 2023 |
| Raymond James | Raymond James | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +435.17% | Nov 14, 2023 |
| Baird | Baird | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +511.62% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.30
from -3.98
EPS Next Year
-2.00
from -2.30
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 8.7M | 310.7M | 392.0M |
| Avg | n/a | n/a | 4.8M | 96.6M | 159.3M |
| Low | n/a | n/a | n/a | 25.5M | 55.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 6,317.4% | 305.8% |
| Avg | - | - | - | 1,895.0% | 64.9% |
| Low | - | - | - | 426.5% | -42.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.87 | -1.67 | -1.58 | 1.60 | 2.08 |
| Avg | -2.30 | -2.00 | -2.00 | -1.39 | -0.49 |
| Low | -2.72 | -2.47 | -2.48 | -3.50 | -2.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.